Antifungal susceptibility patterns of a global collection of fungal isolates: Results of the SENTRY Antifungal Surveillance Program (2013)

Diagnostic Microbiology and Infectious Disease

Volumn 85, Issue 2, 2016, Pages 200-204

  Castanheira, Mariana ^a   Messer, Shawn A ^a   Rhomberg, Paul R ^a   Pfaller, Michael A ^a,b  

^a JMI LABORATORIES   (United States)

^b T2 Biosystems   (United States)

Author keywords

Antifungal susceptibility; Aspergillus; Candida; Surveillance

Indexed keywords

ANIDULAFUNGIN; CASPOFUNGIN; FLUCONAZOLE; MICAFUNGIN; POSACONAZOLE; VORICONAZOLE; ANTIFUNGAL AGENT;

ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; ASPERGILLUS FUMIGATUS; CANDIDA ALBICANS; CANDIDA DUBLINIENSIS; CANDIDA GLABRATA; CANDIDA ORTHOPSILOSIS; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; CLAVISPORA LUSITANIAE; CRYPTOCOCCUS NEOFORMANS; CYP51A GENE; FUNGAL GENE; FUNGAL STRAIN; FUNGUS ISOLATION; GENE SEQUENCE; HUMAN; MEYEROZYMA GUILLIERMONDII; MIC50; MIC90; NONHUMAN; PRIORITY JOURNAL; WICKERHAMOMYCES ANOMALUS; ANTIFUNGAL RESISTANCE; DRUG EFFECTS; EPIDEMIOLOGICAL MONITORING; FUNGUS; HEALTH; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MYCOSIS;

ANTIFUNGAL AGENTS; DRUG RESISTANCE, FUNGAL; EPIDEMIOLOGICAL MONITORING; FUNGI; GLOBAL HEALTH; HUMANS; MICROBIAL SENSITIVITY TESTS; MYCOSES;

EID: 84962385147     PISSN: 07328893     EISSN: 18790070     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2016.02.009     Document Type: Article

References (21)

1. Alexander B.D., Johnson M.D., Pfeiffer C.D., Jimenez-Ortigosa C., Catania J., Booker R., et al. Increasing echinocandin resistance in Candida glabrata: clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations. Clin Infect Dis 2013, 56:1724-1732.
2. Arendrup M.C. Update on antifungal resistance in Aspergillus and Candida. Clin Microbiol Infect 2014, 20(Suppl. 6):42-48.
3. Castanheira M., Woosley L.N., Pfaller M.A., Diekema D.J., Messer S.A., Jones R.N. Low prevalence of fks1 hotspot 1 mutations in a worldwide collection of Candida spp. Antimicrob Agents Chemother 2010, 54:2655-2659.
4. Castanheira M., Woosley L.N., Diekema D.J., Jones R.N., Pfaller M.A. Candida guilliermondii and other species of Candida misidentified as Candida famata: assessment by Vitek2, ITS sequence analysis and matrix-assisted laser desorption ionization-time of flight mass spectrometry in two global surveillance programs. J Clin Microbiol 2013, 51:117-124.
5. Castanheira M., Woosley L.N., Messer S.A., Diekema D.J., Jones R.N., Pfaller M.A. Frequency of fks mutations among Candida glabrata isolates from a 10-year global collection of bloodstream infection isolates. Antimicrob Agents Chemother 2014, 58:577-580.
6. Cleveland A.A., Farley M.M., Harrison L.H., Stein B., Hollick R., Lockhart S.R., et al. Changes in incidence and antifungal drug resistance in candidemia: results from population-based laboratory surveillance in Atlanta and Baltimore, 2008-2011. Clin Infect Dis 2012, 55:1352-1361.
7. Clinical and Laboratory Standards Institute (CLSI) M27-A3. Reference method for broth dilution antifungal susceptibility testing of yeasts 2008, CLSI, Wayne, PA. Third ed.
8. Clinical and Laboratory Standards Institute (CLSI) M38-A2. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi 2008, CLSI, Wayne, PA. Second ed.
9. Espinel-Ingroff A., Chowdhary A., Gonzalez G.M., Lass-Florl C., Martin-Mazuelos E., Meis J., et al. Multicenter study of isavuconazole MIC distributions and epidemiological cutoff values for Aspergillus spp. for the CLSI M38-A2 broth microdilution method. Antimicrob Agents Chemother 2013, 57:3823-3828.
10. Espinel-Ingroff A., Pfaller M.A., Bustamante B., Canton E., Fothergill A., Fuller J., et al. Multilaboratory study of epidemiological cutoff values for detection of resistance in eight Candida species to fluconazole, posaconazole, and voriconazole. Antimicrob Agents Chemother 2014, 58:2006-2012.
11. Espinel-Ingroff A., Chowdhary A., Gonzalez G.M., Guinea J., Hagen F., Meis J.F., et al. Multicenter study of isavuconazole MIC distributions and epidemiological cutoff values for the Cryptococcus neoformans-Cryptococcus gattii species complex using the CLSI M27-A3 broth microdilution method. Antimicrob Agents Chemother 2015, 59:666-668.
12. Freifeld A.G., Bow E.J., Sepkowitz K.A., Boeckh M.J., Ito J.I., Mullen C.A., et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis 2011, 52:427-431.
13. Lockhart S.R., Frade J.P., Etienne K.A., Pfaller M.A., Diekema D.J., Balajee S.A. Azole resistance in Aspergillus fumigatus isolates from the ARTEMIS global surveillance study is primarily due to the TR/L98H mutation in the cyp51A gene. Antimicrob Agents Chemother 2011, 55:4465-4468.
14. Ostrosky-Zeichner L., Pappas P.G. Invasive candidiasis in the intensive care unit. Crit Care Med 2006, 34:857-863.
15. Pappas P.G., Kauffman C.A., Andes D., Clancy C.J., Marr K.A., Ostrosky-Zeichner L., et al. Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis 2016, 62:409-417.
16. Pfaller M.A. Antifungal drug resistance: mechanisms, epidemiology, and consequences for treatment. Am J Med 2012, 125:S3-S13.
17. Pfaller M.A., Diekema D.J., Ghannoum M.A., Rex J.H., Alexander B.D., Andes D., et al. Wild-type MIC distribution and epidemiological cutoff values for Aspergillus fumigatus and three triazoles as determined by the Clinical and Laboratory Standards Institute broth microdilution methods. J Clin Microbiol 2009, 47:3142-3146.
18. Pfaller M.A., Espinel-Ingroff A., Castanheira M., Cuenca-Estrella M., Diekema D.J., Fothergill A., et al. Wild-type MIC distributions and epidemiological cutoff values for amphotericin B, flucytosine, and itraconazole and Candida spp. as determined by CLSI broth microdilution. J Clin Microbiol 2012, 50:2040-2046.
19. Pfaller M.A., Woosley L.N., Messer S.A., Jones R.N., Castanheira M. Significance of molecular identification and antifungal susceptibility of clinically significant yeasts and moulds in a global antifungal surveillance program. Mycopathologia 2012, 174:259-271.
20. Pham C.D., Iqbal N., Bolden C.B., Kuykendall R.J., Harrison L.H., Farley M.M., et al. The role of FKS mutations in C. glabrata: MIC values, echinocandin resistance and multidrug resistance. Antimicrob Agents Chemother 2014, 58:4690-4696.
21. Verweij P.E., Snelders E., Kema G.H., Mellado E., Melchers W.J. Azole resistance in Aspergillus fumigatus: a side-effect of environmental fungicide use?. Lancet Infect Dis 2009, 9:789-795.